Old Web
English
Sign In
Acemap
>
Paper
>
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome
2019
Andrea Visentin
Silvia Imbergamo
Edoardo Scomazzon
Stefano Pravato
Federica Frezzato
Laura Bonaldi
Marco Pizzi
Stefania Vio
Michele Gregianin
Marta Burei
Monica Facco
Gianpietro Semenzato
Francesco Piazza
Livio Trentin
Keywords:
Cancer research
Medicine
Immunology
Lenalidomide
Richter syndrome
breakpoint cluster region
Kinase
Ibrutinib
Idelalisib
Oncology
Leukemia
Diabetes mellitus
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
10
References
12
Citations
NaN
KQI
[]